Somalogic Inc
NASDAQ:SLGC
Intrinsic Value
SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. [ Read More ]
The intrinsic value of one SLGC stock under the Base Case scenario is 3.63 USD. Compared to the current market price of 2.1 USD, Somalogic Inc is Undervalued by 42%.
Valuation Backtest
Somalogic Inc
Run backtest to discover the historical profit from buying and selling SLGC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Somalogic Inc
Current Assets | 494.1m |
Cash & Short-Term Investments | 453.8m |
Receivables | 20.7m |
Other Current Assets | 19.6m |
Non-Current Assets | 70.9m |
PP&E | 18.2m |
Intangibles | 27.1m |
Other Non-Current Assets | 25.6m |
Current Liabilities | 27.8m |
Accounts Payable | 11.5m |
Accrued Liabilities | 12.8m |
Other Current Liabilities | 3.5m |
Non-Current Liabilities | 40.5m |
Other Non-Current Liabilities | 40.5m |
Earnings Waterfall
Somalogic Inc
Revenue
|
81.7m
USD
|
Cost of Revenue
|
-48.1m
USD
|
Gross Profit
|
33.6m
USD
|
Operating Expenses
|
-183.3m
USD
|
Operating Income
|
-149.7m
USD
|
Other Expenses
|
19.3m
USD
|
Net Income
|
-130.4m
USD
|
Free Cash Flow Analysis
Somalogic Inc
What is Free Cash Flow?
SLGC Profitability Score
Profitability Due Diligence
Somalogic Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Somalogic Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
SLGC Solvency Score
Solvency Due Diligence
Somalogic Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
Somalogic Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SLGC Price Targets Summary
Somalogic Inc
According to Wall Street analysts, the average 1-year price target for SLGC is 3.93 USD .
Ownership
SLGC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
SLGC Price
Somalogic Inc
Average Annual Return | -46.72% |
Standard Deviation of Annual Returns | 43.46% |
Max Drawdown | -88% |
Market Capitalization | 396.3m USD |
Shares Outstanding | 188 679 008 |
Percentage of Shares Shorted | 4.23% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
SomaLogic, Inc. is a commercial-stage proteomics company, which built an integrated proteomics platform for robust, high throughput proteomics analysis, research and clinical applications. The company is headquartered in New York City, New York and currently employs 320 full-time employees. The company went IPO on 2021-02-23. The company develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein. The company offers SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. Its products include SomaScan Assay, SomaSignal Tests, SomaScan Panels, and SOMAmer Reagents. SomaScan Assay is utilized for Research Use Only (RUO) applications. Its SomaScan Assay measures approximately 7,000 protein target measurements in a single sample. SomaSignal Tests are available as laboratory developed tests (LDT) for use in obtaining proteomics information from patients and monitoring patients’ physiological states, among others. SomaScan Panels consists of two categories: fixed panels and custom panels. The company offers drug development, analysis of clinical trial and new human biology insights.
Contact
IPO
Employees
Officers
The intrinsic value of one SLGC stock under the Base Case scenario is 3.63 USD.
Compared to the current market price of 2.1 USD, Somalogic Inc is Undervalued by 42%.